<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033279</url>
  </required_header>
  <id_info>
    <org_study_id>09-1158</org_study_id>
    <nct_id>NCT01033279</nct_id>
  </id_info>
  <brief_title>Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy</brief_title>
  <acronym>ESCAPE</acronym>
  <official_title>Evaluation of Self-monitoring of Oral antiCoagulant therApy by the PatiEnts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Diagnostic Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether self-management of oral anticoagulation
      therapy with warfarin has an effect on patient's quality of life following a specific
      training program led by pharmacists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anticoagulation-related quality of life</measure>
    <time_frame>Four months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in therapeutic International Normalized Ratio (INR)</measure>
    <time_frame>Four months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in extended therapeutic INR range</measure>
    <time_frame>Four months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in extreme INR ranges (&lt;1.5 and &gt; 5)</measure>
    <time_frame>Four months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of anticoagulation-related knowledge post training program</measure>
    <time_frame>Four months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent by patients managing their oral anticoagulation</measure>
    <time_frame>Four months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic events</measure>
    <time_frame>Four months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>Four months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Anticoagulants</condition>
  <condition>Quality of Life</condition>
  <condition>Drug Monitoring</condition>
  <condition>Pharmacy</condition>
  <condition>Ambulatory Care</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients followed by usual care at the hospital's anticoagulation clinic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Self-management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Self-monitoring and self-adjustment of oral anticoagulation according to predefined algorithms</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self-monitoring and adjustment of oral anticoagulation</intervention_name>
    <description>Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists</description>
    <arm_group_label>Self-management</arm_group_label>
    <other_name>warfarin</other_name>
    <other_name>coumadin</other_name>
    <other_name>coaguchek XS</other_name>
    <other_name>coaguchek</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 18 years and over followed at the Montreal Heart Institute's
             Anticoagulation clinic

          -  Warfarin treatment planned for at least 4 months after inclusion in the study

          -  Warfarin treatment initiated for at least 6 months

          -  Last 2 INRs between 1.5 and 4 if target INR is between 2 and 3

          -  Last 2 INRS between 2 and 4 if target INR is between 2.5 and 3.5

          -  Provide a signed informed consent

        Exclusion Criteria:

          -  Patient unable to understand (spoken and written) French or English

          -  Patient refuses or is unable to attend the required training sessions

          -  Targeted INR other than 2 to 3 or 2.5 to 3.5

          -  Handicap or physical limitation compromising the patient's ability to initiate
             self-monitoring in the absence of a proxy helper

          -  Moderate to severe cognitive impairment or important comprehension problems

          -  Active neoplasm

          -  Concurrent chemotherapy

          -  Hypercoagulable conditions

          -  Life expectancy of less than 1 year documented in the medical chart

          -  Inclusion (at time of inclusion or 30 days prior to inclusion) in another research
             project involving a drug

          -  Patient anticoagulated with nicoumalone

          -  Pregnancy or breastfeeding

          -  Active bleeding (except for menses)

          -  Recent major bleeding (less than 3 months before inclusion)

          -  Stroke, acute coronary syndrome, percutaneous coronary intervention, coronary artery
             bypass graft, cardiac valve replacement, deep veinous thrombosis or pulmonary embolism
             in the 3 months prior to inclusion

          -  Any other condition that, in the opinion of the investigators, of the treating
             physician or of the healthcare professionals working at the anticoagulation clinic
             could make self-management by the patient impossible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucie Verret, B.Pharm, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Lucie Verret</investigator_full_name>
    <investigator_title>Chief Department of Pharmacy</investigator_title>
  </responsible_party>
  <keyword>Coaguchek</keyword>
  <keyword>Portable coagulometer</keyword>
  <keyword>Self-monitoring</keyword>
  <keyword>Coumadin</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Pharmacist</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

